Chronic, selective forebrain responses to excitotoxic dorsal horn injury.
Intraspinal injection of the AMPA/metabotropic receptor agonist quisqualic acid (QUIS) results in excitotoxic injury which develops pathological characteristics similar to those associated with ischemic and traumatic spinal cord injury (SCI) (R. P. Yezierski et al., 1998, Pain 75: 141-155; R. P. Yezierski et al., 1993, J. Neurotrauma 10: 445-456). Since spinal injury can lead to partial or complete deafferentation of ascending supraspinal structures, it is likely that secondary to the disruption of spinal pathways these regions could undergo significant reorganization. Recently, T. J. Morrow et al. (Pain 75: 355-365) showed that autoradiographic estimates of regional cerebral blood flow (rCBF) can be used to simultaneously identify alterations in the activation of multiple forebrain structures responsive to noxious formalin stimulation. Accordingly, we examined whether excitotoxic SCI produced alterations in the activation of supraspinal structures using rCBF as a marker of neuronal activity. Twenty-four to 41 days after unilateral injection of QUIS into the T12 to L3 spinal segments, we found significant increases in the activation of 7 of 22 supraspinal structures examined. As compared to controls, unstimulated SCI rats exhibited a significant bilateral increase in rCBF within the arcuate nucleus (ARC), the hindlimb region of S1 cortex (HL), parietal cortex (PAR), and the thalamic posterior (PO), ventral lateral (VL), ventral posterior lateral (VPL), and ventral posterior medial (VPM) nuclei. All structures showing significantly altered rCBF are associated with the processing of somatosensory information. These changes constitute remote responses to injury and suggest that widespread functional changes occur within cortical and subcortical regions following injury to the spinal cord.
Morrow
T J
TJ
Neurology Research Laboratory, VA Medical Center, Ann Arbor, Michigan, 48105, USA.
Paulson
P E
PE
Brewer
K L
KL
Yezierski
R P
RP
Casey
K L
KL
D000344:Afferent Pathways; D000818:Animals; D002560:Cerebrovascular Circulation; D002908:Chronic Disease; D018690:Excitatory Amino Acid Agonists; D008297:Male; D009410:Nerve Degeneration / Q000139:chemically induced / Q000503:physiopathology; D009473:Neuronal Plasticity / Q000502:physiology; D009498:Neurotoxins / Q000494:pharmacology; D020671:Posterior Horn Cells / Q000502:physiology*; D016548:Prosencephalon / Q000098:blood supply / Q000166:cytology / Q000502:physiology; D016318:Quisqualic Acid; D051381:Rats; D020318:Rats, Long-Evans; D012678:Sensation Disorders / Q000503:physiopathology; D013003:Somatosensory Cortex / Q000098:blood supply / Q000166:cytology / Q000502:physiology*; D013119:Spinal Cord Injuries / Q000503:physiopathology
D018690:Excitatory Amino Acid Agonists; D009498:Neurotoxins; D016318:Quisqualic Acid